Home Page

NEW ORLEANS, July 21, 2021 /PRNewswire-PRWeb/ -- Ochsner Health, headquartered in New Orleans, is improving the future of healthcare by piloting a pharmacogenomics project that will help predict which drugs will work best for individual patients before they even need them by adding the ActX Genomic Decision Support to its Electronic Health Record, Epic. The goal is to transform patient care and bring precision medicine into the workflow of Ochsner's physicians.

The key advantages of the ActX genomics platform include real time drug genome interaction checking within normal electronic health record order workflow, a built-in genomic profile in each chart, and the ability to assess actionable hereditary risks.

Ochsner will integrate ActX Genomic Decision Support within its electronic health record, Epic. This integration brings genomics to cancer care by leveraging the ActX service to enable real-time checking of each prescription order against the patient's genetic profile. Prescribing physicians will be alerted if a drug is likely to be ineffective, cause an adverse reaction, or need a dosing change based on the patient's genetics, all within their normal prescribing workflow. A built-in Genomic Profile for each patient will be available within the patient chart.

"The ability to predict ahead of time which drugs will be effective for a unique patient across many different clinical scenarios and to identify in real-time which medications may cause patients serious issues, will save lives and improve the quality of our care while also being more cost effective," said Marc Matrana, MD, MS, FACP, Director, Ochsner Precision Cancer Therapies Program.

"We are excited to partner with Ochsner Health to bring precision medicine and genomic decision support into routine care," said Dr. Andrew Ury, CEO of ActX. "The ActX Platform will help make actionable genomics practical for Ochsner's physicians and their patients."

Ochsner's implementation of ActX within Epic marks a big step toward making personalized medicine the norm for its patients. To learn more about ActX, visit http://www.actx.com.

About ActX

ActX helps physicians make better decisions about medical treatment, using patients' genetic information. ActX uses its GenoACT? clinical decision support program to analyze a patient's genetic information and alert physicians in real time through their existing workflow tools about drug-genome interactions, actionable hereditary risks and carrier status. For more information, visit http://www.actx.com, email info@actx.com or call (888) 998-2289.

About Ochsner Health

Ochsner Health is a system that delivers health to the people of Louisiana, Mississippi and the Gulf South with a mission to Serve, Heal, Lead, Educate and Innovate. Ochsner Health is a not-for-profit committed to giving back to the communities it serves through preventative screenings, health and wellness resources and partnerships with innovative organizations that share our vision. Ochsner Health healed more than 900,000 people from across the globe in 2020, providing the latest medical breakthroughs and therapies, including digital medicine for chronic conditions and telehealth specialty services. Ochsner Health is a national leader, named the top hospital in Louisiana and a top children's hospital by U.S. News & World Report. As Louisiana's leading healthcare educator, Ochsner Health and its partners educate thousands of healthcare professionals annually. Ochsner Health is innovating healthcare by investing in new technologies and research to make world-class care more accessible, affordable, convenient and effective. Ochsner's team of more than 32,000 employees and 4,500 providers are working to reinvent the future of health and wellness in the region. To learn more about Ochsner Health, please visit http://www.ochsner.org. To transform your health, please visit http://www.ochsner.org/healthyyou.

Epic is a registered trademark of Epic Systems Corporation.

Media Contact

Joe Sichel, ActX, +1 (888) 998-2289 Ext: 101, joe.sichel@actx.com

Twitter, Facebook

SOURCE ActX